• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
MLN8237

MLN8237

Product ID M4652
Cas No. 1028486-01-2
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $118.00 In stock
5 mg $219.00 In stock
10 mg $337.00 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

MLN8237 inhibits aurora kinase A (AurA) preventing mitotic spindle formation and proper completion of mitosis. MLN8237 exhibits anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for multiple myeloma, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia (CLL). In bladder cancer cells, MLN8237 induces cell cycle arrest, aneuploidy, and apoptosis; in animal models of bladder cancer, this compound inhibits tumor growth. Additionally, MLN8237 inhibits tumor growth of neuroblastomas in vivo as well. In HUVECs, MLN8237 decreases tubule formation and inhibits VEGF secretion, suggesting potential anti-angiogenic activity.

Product Info

Cas No.

1028486-01-2

Purity

≥98%

Formula

C27H20ClFN4O4

Formula Wt.

518.92

IUPAC Name

4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid

Synonym

Alisertib

Solubility

DMSO 27 mg/mL (52.03 mM) Water Insoluble Ethanol Insoluble

Appearance

Pale Yellow Powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

M4652 MSDS PDF

Info Sheet

M4652 Info Sheet PDF

References

Romain C, Paul P, Kim KW, et al. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma. J Pediatr Surg. 2014 Jan;49(1):159-65. PMID: 24439602.

Kelly KR, Shea TC, Goy A, et al. Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs. 2013 Dec 20. [Epub ahead of print]. PMID: 24352795.

Zhou N, Singh K, Mir MC, et al. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res. 2013 Apr 1;19(7):1717-28. PMID: 23403633.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • P8270

    Purvalanol A

    Purine derivative; CDK inhibitor.

    ≥98%
  • F5868

    Formoterol Fumarate Dihydrate

    β2-adrenergic agonist.

    ≥98%
  • F4783

    Fluvoxamine Maleate

    FIASMA, 5-HT3 and σ1 agonist, SERT inhibitor.<...

    ≥97%
  • A971334

    Azilsartan

    Sartan

    ≥98%
  • S1968

    Seratrodast

    TxA2 antagonist.

    ≥99%
  • P1755

    Pentoxifylline

    Xanthine derivative; adenosine A2 antagonist, P...

    ≥98%
  • B6935

    Brivudine

    Nucleoside (thymidine) analog; DNA chain termin...

    ≥98%
  • G0179

    Gastrin-1, rat

    Endogenous peptide hormone; CCK2 agonist, indir...

    ≥95%
  • J6400

    (+)-JQ-1

    Triazolothienodiazepine; BRD inhibitor.

    ≥99%
  • T2934

    Thiamphenicol Palmitate

    Chloramphenicol derivative; protein translation...

    ≥98%
  • C3246

    Cilostazol

    Quinoline; PDE 3B inhibitor.

    ≥98%
  • T6935

    Trimebutine Base

    BK K+ channel and L-type Ca2+ channel blocker.<...

    ≥97%
  • D1859

    2-Deoxy-D-glucose

    Glucose metabolism inhibitor, N-linked glycosyl...

    ≥99%
  • E4902

    Emamectin B1 Benzoate

    Semi-synthetic avermectin; GABA potentiator.

    ≥80%
  • N0062

    D,L-Naproxen

    NSAID; COX-1/2 inhibitor.

    ≥98%
  • A5132

    Amikacin Disulfate

    Aminoglycoside; protein translation inhibitor.<...

    ≥98%
  • C3479

    Citrinin

    Mycotoxin produced by Penicillum, Aspergillus, ...

    ≥98%
  • T1750

    Temocapril Hydrochloride

    ACE inhibitor.

    ≥98%
  • T7033

    Trifluoperazine Dihydrochloride

    Phenothiazine; D1/2 and α1-adrenergic antagoni...

    ≥98%
  • M1679

    Methysticin

    Kavalactone originally found in Piper methystic...

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2026 LKT Laboratories, All Rights Reserved - Products for research use only